Author

B. H. Segal

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2 Research Focus:cell-cell communication· 1

Frequent Co-Authors

K. Odunsi· 2 shared A. M. Intlekofer· 1 shared A. N. H. Khan· 1 shared A. N. Lane· 1 shared A. P. Sharda· 1 shared A. R. McGray· 1 shared B. A. Davidson· 1 shared B. D. Litchy· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

K. Odunsi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ARS2-directed alternative splicing mediates CD28 driven T cell glycolysis and effector function

G. A. Holling, A. P. Sharda, M. M. Honikel, C. M. James, S. M. Lightman, G. Qiao, K. L. Singel, T. R. Emmons, T. Giridharan, S. Hou, A. M. Intlekofer, R. M. Higashi, T. W. M. Fan, A. N. Lane, K. H. Eng, , S. H. Olejniczak

This study shows ARS2 promotes CD28-driven T cell glycolysis and effector function through alternative splicing of Pkm2, enhancing anti-tumor immunity.

bioRxiv · May 7, 2021 · PreprintImmunology

A circulating T-cell differentiation marker to predict response to immune checkpoint inhibitors

T. Yamauchi, T. Hoki, T. Oba, V. Jain, H. Chen, K. Attwood, S. Battaglia, S. George, G. Chatta, I. Puzanov, C. Morrison, K. Odunsi, B. H. Segal, G. K. Dy, M. S. Ernstoff, F. Ito

The paper identifies CX3CR1 expression on circulating CD8+ T cells as a biomarker predicting response to immune checkpoint inhibitor therapy in NSCLC patients.

bioRxiv · Jun 13, 2020Immunology

RNA editing enzyme APOBEC3A promotes pro-inflammatory (M1) macrophage polarization

E. Y. Alqassim, S. Sharma, A. N. H. Khan, T. Emmons, E. Cortes-Gomez, K. Singel, J. Mark, B. A. Davidson, A. R. McGray, Q. Liu, B. D. Litchy, K. Moysich, J. Wang, K. Odunsi, B. H. Segal, B. E. Baysal

This study shows APOBEC3A promotes M1 macrophage polarization through RNA editing, affecting gene expression and cytokine secretion.

bioRxiv · Mar 20, 2020Immunology